Aveva Drug Delivery Systems, Inc
FDA 503B outsourcing facility
Tamarac, Florida
Key Takeaways
- FDA-registered 503B outsourcing facility since 2024
- Sterile compounding from bulk substances: Yes
- Not yet inspected by the FDA
- 3 FDA drug recalls on record (2023 to 2026)
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- November 4, 2024
- Most recent registration
- November 25, 2025
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- Not yet inspected
Aveva Drug Delivery Systems, Inc has registered with the FDA as a 503B outsourcing facility but has not yet been inspected. The FDA inspects registered facilities on a risk-based schedule once drug production and distribution are confirmed.
FDA recall history
Aveva Drug Delivery Systems, Inc has 3 FDA drug recalls on record between 2023 and 2026, based on the FDA enforcement database. Breakdown: 3 Class III.
Recall reasons on record include failed impurities/degradation specifications: elevated levels of oxidative-related; failed impurities/degradation specifications: out of specification for related substance.
| Date | Class | Product | Reason |
|---|---|---|---|
| May 2026 | Class III | Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva, Distributed by: RUGBY LABORATORIES, Indianapolis, IN 46268, www.majorph | Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, exceeding shelf-life specifications during stability testing of individual units. |
| February 2023 | Class III | Buprenorphine Transdermal System, CIII 20 mcg/hour, 4 Transdermal Systems One package of 4 disposal units, Rx Only, Manufactured by: Aveva D | Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint. |
| February 2023 | Class III | Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of 4 disposal units, Rx Only, Manufactured by: Aveva D | Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint. |
FDA recall classes signal severity, not intent: Class I means a reasonable probability of serious harm, Class II a temporary or reversible risk, Class III a violation unlikely to cause harm. Sterile compounders routinely recall lots as a precaution. FDA definitions.
Compounded peptides and GLP-1s
Aveva Drug Delivery Systems, Inc has not assigned NDCs or filed product reports in the most recent FDA reporting periods. 503B outsourcing facilities are a primary supply route for compounded peptides and GLP-1s during FDA-listed shortages; PeptideGrids grades the evidence for each, including Semaglutide, Tirzepatide, BPC-157, Retatrutide. Browse the GLP-1 and therapeutic peptide databases.
Location
3250 Commerce Pkwy, Miramar, FL 33025-3907
Satellite and street imagery via Esri. Open larger map.
Contact
FDA-registered contact: Madhuri Gupta, 1-954-218-1570. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Aveva Drug Delivery Systems, Inc with the Florida Board of Pharmacy.
503B facilities in Florida
Florida has 16 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in Florida.
Frequently asked questions
Is Aveva Drug Delivery Systems, Inc registered with the FDA?
Yes. Aveva Drug Delivery Systems, Inc is a registered 503B outsourcing facility, first registered with the FDA on November 4, 2024 and most recently registered on November 25, 2025.
Has Aveva Drug Delivery Systems, Inc been inspected by the FDA?
Aveva Drug Delivery Systems, Inc has registered with the FDA but has not yet been inspected as a 503B outsourcing facility.
Has Aveva Drug Delivery Systems, Inc had any FDA drug recalls?
Aveva Drug Delivery Systems, Inc has 3 FDA drug recalls on record (2023 to 2026) in the FDA enforcement database.
What does Aveva Drug Delivery Systems, Inc compound?
Aveva Drug Delivery Systems, Inc has not filed product reports with NDC-assigned drugs in the most recent FDA reporting periods.
Where is Aveva Drug Delivery Systems, Inc located?
Aveva Drug Delivery Systems, Inc is located in Tamarac, Florida (3250 Commerce Pkwy).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026. Recall history from the FDA openFDA drug enforcement database, retrieved June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Aveva Drug Delivery Systems, Inc. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.